<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01208532</url>
  </required_header>
  <id_info>
    <org_study_id>HDC29_Kor</org_study_id>
    <nct_id>NCT01208532</nct_id>
  </id_info>
  <brief_title>Validation Study of the Korean Version of the EORTC QLQ-HDC29</brief_title>
  <official_title>Quality of Life in Patients With Stem Cell Transplant After High Dose Chemotherapy: Validation Study of the Korean Version of the EORTC QLQ-HDC29</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the reliability and validity of the Korean version of
      the European Organization for Research and Treatment of Cancer High-dose Chemotherapy module
      (EORTC HDC-29).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model:  Case-Only, Time Perspective:  Prospective</study_design>
  <primary_outcome>
    <measure>Reliability and validity of the Korean version of the EORTC HDC-29</measure>
    <time_frame>at the patient's hospitalization (before the SCT) and the outpatient clinic (three, six, and 12 months after their SCT)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Relaibility; Cronbach's alpha coefficient is used to evaluate the internal consistency.
Validity; Persons's correlation coefficient is used to examine the correlation between similar dimensions of the different questionnaires.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stem Cell Transplantation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are diagnosed with hematologic malignancies and who are planned to recieve
        high-dose chemotherapy followed by allo or auto stem cell transplantation in Seoul
        National University Hospital, Korea
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are aged more than 18 years

          -  Patients who are diagnosed with hematologic malignancies and who are       planned to
             receive high-dose chemotherapy followed by allogeneic or autologous stem cell
             transplantation (SCT)

          -  Patients who agree with the informed consent

        Exclusion Criteria:

          -  Patients who are unable to complete the questionnaire due to the serious physical or
             psychological morbidity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Soo Yoon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung Mi Oh, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>College of Pharmacy, Seoul National University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung-Soo Yoon, MD, PhD</last_name>
    <phone>+82-2-2072-3079</phone>
    <email>ssysmc@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyung Im Kim, M.S.</last_name>
    <phone>+82-2-2072-0335</phone>
    <email>00zzanga@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Soo Yoon, MD, PhD</last_name>
      <phone>+82-2-2072-3079</phone>
      <email>ssysmc@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Kyung Im Kim, M.S.</last_name>
      <phone>+82-2-2072-0335</phone>
      <email>00zzanga@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sung-Soo Yoon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jung Mi Oh, Pharm.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byoung Kook Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seonyang Park, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inho Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyung Im Kim, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Velikova G, Weis J, Hjermstad MJ, Kopp M, Morris P, Watson M, Sezer O; EORTC Quality of Life Group. The EORTC QLQ-HDC29: a supplementary module assessing the quality of life during and after high-dose chemotherapy and stem cell transplantation. Eur J Cancer. 2007 Jan;43(1):87-94. Epub 2006 Nov 1.</citation>
    <PMID>17081744</PMID>
  </reference>
  <reference>
    <citation>Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, You CH, West K. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res. 2004 May;13(4):863-8.</citation>
    <PMID>15129896</PMID>
  </reference>
  <reference>
    <citation>Han CW, Lee EJ, Iwaya T, Kataoka H, Kohzuki M. Development of the Korean version of Short-Form 36-Item Health Survey: health related QOL of healthy elderly people and elderly patients in Korea. Tohoku J Exp Med. 2004 Jul;203(3):189-94.</citation>
    <PMID>15240928</PMID>
  </reference>
  <reference>
    <citation>Yoo H, Lee K, Lee J, Eremenco S, Choi S, Kim H, Lee J. Korean translation and validity of FACT-BMT version 4 and the quality of life in allogeneic bone marrow transplantation patients. Qual Life Res. 2006 Apr;15(3):559-64.</citation>
    <PMID>16547794</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 20, 2011</lastchanged_date>
  <firstreceived_date>September 23, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Sung-Soo Yoon, MD, PhD / Professor</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
</clinical_study>
